PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35081714-0 2022 Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. pyrimidine 30-40 ret proto-oncogene Homo sapiens 63-66 35081714-0 2022 Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. pyrimidine 30-40 ret proto-oncogene Homo sapiens 71-74 35081714-7 2022 Collectively, N-trisubstituted pyrimidine derivatives could serve as scaffolds for the discovery and development of potent inhibitors of type I RET and its gatekeeper mutant for the treatment of RET-driven cancers. pyrimidine 31-41 ret proto-oncogene Homo sapiens 144-147 35081714-7 2022 Collectively, N-trisubstituted pyrimidine derivatives could serve as scaffolds for the discovery and development of potent inhibitors of type I RET and its gatekeeper mutant for the treatment of RET-driven cancers. pyrimidine 31-41 ret proto-oncogene Homo sapiens 195-198